198 related articles for article (PubMed ID: 21944959)
1. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
Classe JM; Jaffre I; Frenel JS; Bordes V; Dejode M; Dravet F; Ferron G; Marchal F; Rigaud DB; Loussouarn D; Campion L
Eur J Surg Oncol; 2011 Nov; 37(11):971-7. PubMed ID: 21944959
[TBL] [Abstract][Full Text] [Related]
2. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
3. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of risk factors for epithelial ovarian cancer recurrence].
Liu S; Liu JH; Huang H; Peng XP; Wang YM
Ai Zheng; 2003 Nov; 22(11):1197-200. PubMed ID: 14613652
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
[TBL] [Abstract][Full Text] [Related]
6. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
[TBL] [Abstract][Full Text] [Related]
7. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
[TBL] [Abstract][Full Text] [Related]
10. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
12. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
16. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
17. Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital.
Lertkhachonsuk R; Manchana T; Termrungruanglert W; Vasuratna A; Sittisomwong T; Worasethsin P; Sirisabya N; Khemapech N; Tresukosol D
J Med Assoc Thai; 2006 Feb; 89(2):138-44. PubMed ID: 16578998
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
20. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]